Sanofi, Novavax Sign $1.2B Deal For One-Shot COVID, Flu Jab
Sanofi and U.S. vaccine developer Novavax Inc. said on Friday that the French pharmaceutical company has bought a co-exclusive licensing agreement worth up to $1.2 billion, part of a collaboration to...To view the full article, register now.
Already a subscriber? Click here to view full article